drugset / Trial / NCT01061788
A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007
Phase 1
Completed
43 enrolled
Jeffrey Clarke
NantCell, Inc. · collabNovartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
This open-label, non-randomized, dose escalation phase I biomarker trial of the triplet regimen of AMG 479, everolimus, and panitumumab for subjects with refractory advanced solid tumors is designed to assess the safety and tolerability of this combination as well as preliminary efficacy.
Timeline
- Start
- 2010-04
- Primary completion
- 2018-12-19
- Completion
- 2018-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | — | Oral |
| Subject | Ganitumab | Monoclonal antibody | — | Intravenous |
| Subject | Panitumumab | Monoclonal antibody | — | Intravenous |